The CpG Island Methylator Phenotype (CIMP)

A Coordinated Methylation Programme

CIMP is identified by testing a panel of marker loci; a tumour methylated at most of them is called CIMP-high. The phenotype implies that something has systematically driven promoter methylation rather than a series of independent events.

In colorectal cancer, CIMP-high tumours are strongly associated with BRAF V600E mutation and arise preferentially from sessile serrated lesions rather than conventional adenomas.

The Link to MLH1 and Microsatellite Instability

A major consequence of CIMP in colorectal cancer is methylation of the MLH1 promoter, which silences this mismatch-repair gene and produces sporadic microsatellite instability. This is the mechanism behind most MSI-high colorectal cancers that are not due to Lynch syndrome.

So a CIMP-high, BRAF-mutant, MLH1-methylated tumour profile argues against an inherited cause, whereas MSI without these features raises the possibility of Lynch syndrome.

Caveats

There is no single agreed marker panel or threshold for CIMP, so prevalence and prognostic associations differ between studies and cancer types. CIMP in glioma (linked to IDH mutation) is biologically distinct from colorectal CIMP.

CIMP status is mainly used in research and in interpreting the origin of microsatellite instability, not as a direct treatment selector.

How CIMP Informs Interpretation

The practical payoff of a CIMP assessment in colorectal cancer is in interpreting microsatellite instability. A CIMP-high, BRAF V600E, MLH1-methylated pattern points to a sporadic cause and argues against Lynch syndrome, sparing unnecessary germline testing, whereas microsatellite instability without those features keeps an inherited cause on the table.

CIMP itself is not used to select a drug. BRAF-mutant colorectal cancers, which overlap heavily with CIMP-high disease, are treated with a BRAF inhibitor plus an anti-EGFR antibody, but that decision follows the BRAF result rather than the methylator phenotype.

Key Takeaways

• ·CIMP describes coordinated hypermethylation of many promoter CpG islands in a tumour.
• ·Colorectal CIMP is linked to BRAF V600E and to MLH1 silencing causing sporadic MSI.
• ·Definitions vary between studies, and glioma CIMP is a separate, IDH-driven phenomenon.